Fda

(Image: Getty/Milkos)

FDA makes example out of Chinese OTC manufacturer

By Ben Hargreaves

The FDA posted a public missive alongside a warning letter to a Chinese OTC drug manufacturer, highlighting the efforts it had been making to address data integrity issues.

(Image: Getty/bong hyungjung)

The sartan saga: Recapping the recalls

By Maggie Lynch

After 2018 saw numerous sartan drugs recalled for possible carcinogenic impurities, in 2019, the industry kept an eye on the regulatory issues that followed and the breakthroughs that have mitigated some of the risks.

(Image: Getty/Martin Barraud)

July roundup: Regulators experience a busy month

By Ben Hargreaves

July has seen a number of actions taken by regulators to manage the supply of medicine, including a crackdown on CBD manufacturers and repackers of opioid medication.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers